Objective To investigate the effects of vaporized perfluorocarbon( PFC) inhalation on histopathology of lung, small intestine, liver and kidney of acute lung-injured rabbits. Methods Eighteen New Zealand rabbits were randomly divided into 3 groups, ie. a conventional mechanical ventilation( CMV)group, a PFC group, and a control group. The rabbits were mechanical ventilated and intratracheally infused artificial seawater to induce acute lung injury. After ALI was established( PaO2 /FiO2 lt; 200 mm Hg) , the CMV group received CMV for 6 hours. The PFC group received PFC inhalation for 2 hours, and followed by CMV for 4 hours. And the control group was weaned from ventilation. Then they were sacrificed for histopathological measurement of lung, small intestine, liver and kidney. Results The rabbits in the control group died in 15 minutes after discontinuation of ventilation. Vaporized PFC inhalation can obviously improve oxygenation and attenuate the damage of the lung in contrast to CMV. Mild improvement was observed in small intestine, liver and kidney after vaporized PFC inhalation, but without statistical significance. Conclusion Vaporized PFC inhalation can improve oxygenation and attenuate lung injury in histopathology,but have no apparent protective effects on extra-pulmonary organs.
Objective To analyze the impact of ivaroxaban on hidden blood loss and blood transfusion rate after primary total knee arthroplasty (TKA) by comparing with the use of low molecular weight heparin. Methods Between December 2009 and January 2011, the clinical data from 90 patients undergoing primary TKA were retrospectively analyzed. At 12 hours after operation, 45 patients were given ivaroxaban (10 mg/d) in the trial group and low molecular weight heparin injection (0.4 mL/d) in the control group for 14 days, respectively. There was no significant difference in gender, age, disease duration, or range of motion between 2 groups (P gt; 0.05). Results The operation time was (92.32 ± 23.13) minutes in the trial group and (89.81 ± 18.65) minutes in the control group, showing no significant difference (t=0.26, P=0.79). The hidden blood loss was (40.18 ± 14.85) g/L in the trial group and (34.04 ± 12.96) g/L in the control group, showing significant difference (t=2.09, P=0.00); the dominant blood loss was (30.60 ± 2.89) g/L and (28.85 ± 8.10) g/L respectively, showing no significant difference (t= 1.37, P=0.17). The blood transfusion rate was 73.33% (33/45) in the trial group and 55.56% (25/45) in the control group, showing no sigificant difference (χ2=3.10, P=0.08); the transfusion volume was (1.44 ± 1.09) U and (1.06 ± 1.17) U respectively, showing no significant difference (t=1.58, P=0.11). Stress ulcer occurred in 1 case of the trial group; symptomatic deep vein thrombosis of lower extremity and asymptomatic muscular venous thrombosis developed in 1 case and 4 cases of the control group respectively. Conclusion Ivaroxaban has effect on the hidden blood loss after primary TKA, which may increase postoperative blood loss and blood transfusion rate. The changes in hemoglobin should be monitored during the anticoagulant therapy, and the blood volume should be added promptly.